SurModics (SRDX) Tops Q2 EPS by 15c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. BBIO
5. NVDA
6. GOOGL
7. OPCH
8. CHRW
9. AMD
10. HUBS

Go back to SurModics (SRDX) Tops Q2 EPS by 15c, Revenues Beat

Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update

April 29, 2020 4:05 PM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.

Summary of Second Quarter and Recent Highlights

Revenue of $22.8 million, an increase of 1% year-over-year GAAP EPS of $0.11, non-GAAP EPS of $0.04 Cash and short-term investments of $48.4 million CE Mark clearance received for Telemark coronary/peripheral support microcatheter Partnership announced with Cook Medical for... More